Aviso: Este site agrega dados públicos oficiais da FDA, ClinicalTrials.gov, PubMed e SEC EDGAR apenas para referência geral. Não constitui aconselhamento médico, diagnóstico, recomendação de tratamento ou aconselhamento de investimento.

Ensaio clínico

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NCT: NCT06329570 · SUSPENDED

ID NCTNCT06329570
EstadoSUSPENDED
Data de início2024-10-22
Conclusão2028-03-31
SponsorNaviFUS Corporation (INDUSTRY)
First posted
Last updated

Resumo breve

This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.

Fonte oficial

Ver no ClinicalTrials.gov →

Dados provenientes da API do ClinicalTrials.gov. Para consultar o estado mais recente, veja o registo oficial.

↑